Table 1.
Demographic and clinical characteristics at baseline
| All patients |
Patients with biomarker profile at baseline |
Patients with biomarker profile at baseline and at first disease evaluation |
|
|---|---|---|---|
| N = 65 | N = 57 | N = 46 | |
| Age (years) | |||
| Median (Q1-Q3) | 70.9 (63.7-77.1) | 70.9 (63.7-75.6) | 69.3 (63.7-75.0) |
| Female sex, n (%) | 21 (32.3) | 20 (35.1) | 17 (37.0) |
| Race, n (%) | |||
| Asian | 1 (1.5) | 0 (0.0) | 0 (0.0) |
| Black or African American | 1 (1.5) | 0 (0.0) | 0 (0.0) |
| White | 63 (96.9) | 57 (100.0) | 46 (100.0) |
| Smoking habits, n (%)a | |||
| Current | 15 (23.1) | 13 (22.8) | 12 (26.1) |
| Former | 42 (64.6) | 38 (66.7) | 28 (60.9) |
| Never | 8 (12.3) | 6 (10.5) | 6 (13.0) |
| ECOG performance status, n (%) | |||
| 0 | 23 (35.4) | 22 (38.6) | 20 (43.5) |
| 1 | 30 (46.2) | 25 (43.9) | 20 (43.5) |
| 2 | 12 (18.5) | 10 (17.5) | 6 (13.0) |
| Histology, n (%) | |||
| Non-squamous | 54 (83.1) | 49 (86.0) | 42 (91.3) |
| Squamous | 11 (16.9) | 8 (14.0) | 4 (8.7) |
| Number of metastatic sites, n (%) | |||
| 0-2 | 47 (72.3) | 44 (77.2) | 38 (82.6) |
| >2 | 18 (27.7) | 13 (22.8) | 8 (17.4) |
| Liver metastases, n (%) | 5 (7.7) | 3 (5.3) | 3 (6.5) |
| Brain metastases, n (%) | 10 (15.4) | 8 (14.0) | 8 (17.4) |
| Bone metastases, n (%) | 10 (15.4) | 8 (14.0) | 8 (17.4) |
| Clinical staging at study entry (TNM seventh edition), n (%) | |||
| IIIB | 3 (4.6) | 3 (5.3) | 2 (4.3) |
| IV | 62 (95.4) | 54 (94.7) | 44 (95.7) |
| Categorical PD-L1 status, n (%) | |||
| 0 | 19 (29.2) | 17 (29.8) | 14 (30.4) |
| 1-49 | 46 (70.8) | 40 (70.2) | 32 (69.6) |
| Continuous PD-L1 status | |||
| Mean (SD) | 12.1 (16.7) | 11.2 (15.6) | 9.6 (13.9) |
| Median (Q1-Q3) | 2.3 (0.0-20.0) | 2.3 (0.0-20.0) | 2.0 (0.0-10.0) |
| Missing | 3 | 3 | 1 |
| Neo/adjuvant chemotherapy, n (%) | |||
| No | 62 (95.4) | 55 (96.5) | 45 (97.8) |
| Yes | 3 (4.6) | 2 (3.5) | 1 (2.2) |
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; Q1-Q3, first and third quartile; SD, standard deviation; TNM, tumor–node–metastasis.
a
Current smokers: more than 100 cigarettes smoked in life, smokers in the last six months; former smokers: at least 100 cigarettes smoked in life, non smokers for at least 6 months; never smokers: less than 100 cigarettes smoked in life.